Carboxylated Psilocybin Derivatives for Lower Side Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing psilocybin compounds, despite their therapeutic potential, are associated with adverse side effects such as panic attacks, paranoia, and psychotic states, necessitating the development of improved derivatives with reduced toxicity and enhanced therapeutic efficacy.
Innovation Solution
The development of carboxylated psilocybin derivatives, where at least one of R2, R5, or R7 is a carboxyl group or a carboxylic acid derivative, and the introduction of these derivatives into pharmaceutical and recreational drug formulations, along with methods for their synthesis and use in treating psychiatric disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If psilocybin compounds are used for therapeutic purposes, then therapeutic potential is improved, but adverse side effects increase
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of psilocybin through carboxylation at specific positions (C-5, C-6, C-7, or C-2) to create derivatives with altered pharmacological properties. This structural modification changes the interaction with 5-HT2A receptors, reducing adverse effects while maintaining or enhancing therapeutic benefits for conditions like depression and anxiety
Solution Approach 2:
The invention implements local quality by introducing carboxyl groups at specific localized positions on the psilocybin molecule rather than uniformly modifying the entire structure. This targeted modification at specific carbon positions allows selective alteration of receptor binding properties, achieving reduced toxicity while preserving therapeutic activity
2Reliability
If carboxylated psilocybin derivatives are synthesized, then therapeutic efficacy is improved, but manufacturing complexity increases
Solution Approach 1:
The synthesis process is segmented into distinct stages: (1) carboxylation of psilocybin at specific positions using reagents like diethyl carbonate or carbon dioxide with base catalysts, (2) purification of the carboxylated derivative, and (3) formulation. This segmentation allows each step to be optimized independently, managing manufacturing complexity while achieving the desired therapeutic efficacy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The carboxylated psilocybin derivatives offer reduced toxicity and improved therapeutic efficacy, particularly in modulating 5-HT2A and 5-HT1A receptors, providing potential treatments for psychiatric disorders with reduced adverse effects.
Implementation Method 1
thereby modulating 5-HT2A and 5-HT1A receptor activity
Data Source
AI summary
Disclosed are novel carboxylated psilocybin derivative compounds and pharmaceutical and recreational drug formulations containing the same. The compounds may be produced by reacting a reactant psilocybin derivative with a carboxyl or Carboxylic acid derivative containing compound.